318 related articles for article (PubMed ID: 37316449)
1. [Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
Li J; Yao X; Qiu L; Zhang R; Wang G
Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):392-399. PubMed ID: 37316449
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
3. [Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Ma L; Diao B; Huang Z; Wang B; Yu J; Meng X
Cancer Commun (Lond); 2021 Dec; 41(12):1314-1330. PubMed ID: 34699691
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao M; Jiang T; Liu X; Mao S; Zhou F; Li X; Zhao C; Chen X; Su C; Ren S; Zhou C
J Thorac Oncol; 2021 Aug; 16(8):1267-1288. PubMed ID: 33915248
[TBL] [Abstract][Full Text] [Related]
6. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu Y; Miao J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):934-942. PubMed ID: 38163979
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
8. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in advanced non-small-cell lung cancer with
Liu F; Yuan X; Jiang J; Chu Q
Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
11. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
Front Immunol; 2022; 13():931718. PubMed ID: 35990690
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].
Ma L; Qin N; Zhang X; Wu Y; Li H; Yu M; Liu Z; Wang J
Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):338-344. PubMed ID: 34034457
[TBL] [Abstract][Full Text] [Related]
13. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
[TBL] [Abstract][Full Text] [Related]
15. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Yamada T; Hirai S; Katayama Y; Yoshimura A; Shiotsu S; Watanabe S; Kikuchi T; Hirose K; Kubota Y; Chihara Y; Harada T; Tanimura K; Takeda T; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancer Med; 2019 Apr; 8(4):1521-1529. PubMed ID: 30790471
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
18. [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
Chen R; Jiang C; Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):601-608. PubMed ID: 36002197
[TBL] [Abstract][Full Text] [Related]
19. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
20. [Study Progression on Non-small Cell Lung Cancer with EGFR Mutation
Treated by Immune Checkpoint Inhibitors].
Bai R; Chen N; Cui J
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):641-648. PubMed ID: 30172273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]